“Rosetta Stone” of cell signaling could expedite precision cancer medicine
An atlas of human protein kinases enables scientists to map cell signaling pathways with unprecedented speed and detail.
An atlas of human protein kinases enables scientists to map cell signaling pathways with unprecedented speed and detail.
MIT researchers find circadian variations in liver function play an important role in how drugs are broken down in the body.
New CLAUDIA system could continuously monitor patients during an infusion and adjust dosage to maintain optimal drug levels.
An MIT Values event showcased three women's career journeys and how they are paving the way for the next generation.
For 10th consecutive year, the Institute ranks No. 2 among all colleges and No. 1 among colleges with one main campus, underlying the impact of innovation and critical role of technology transfer.
In MIT’s 2024 Killian Lecture, chemical engineer Paula Hammond described her groundbreaking work on nanoparticles designed to attack tumor cells.
Joining three teams backed by a total of $75 million, MIT researchers will tackle some of cancer’s toughest challenges.
With the new technique, MIT researchers hope to identify mutations that could be targeted with new cancer therapies.
Study shows metal-organic particles can both deliver vaccines and act as an adjuvant to generate a strong immune response at a lower dose.
A new study finds precancerous colon cells turn on a gene called SOX17, which helps them evade detection and develop into more advanced tumors.
Thirteen postdocs join program that emphasizes community and prioritizes professional development.
Albert Almada PhD ’13 studies the mechanics of how stem cells rebuild tissues. “Digging deep into the science is what MIT taught me,” he says.
Award honors “scientists who have made a transformational contribution toward the improvement of human health.”
Two professors and three additional alumni recognized for “dreaming up solutions to global challenges — advancing health, sustainability, and human connection.”
Awarded $65.67 million from ARPA-H, the researchers will work to develop ingestible capsules that deliver mRNA and electric stimuli to treat metabolic disorders such as diabetes.